{
    "nctId": "NCT02688998",
    "briefTitle": "REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab",
    "officialTitle": "Simple, Prospective and Randomized Trial to Obtain Answers to Questions of Standard of Care: Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab: A Study From the REthinking Clinical Trials Program (REaCT-vascular Access Her2 Negative).",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "HEALTH_SERVICES_RESEARCH",
    "enrollmentCount": 150,
    "primaryOutcomeMeasure": "Accrual rates",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed primary breast cancer\n* Planned to start either FEC-D, AC-D, dose-dense AC-T, TAC, or TC chemotherapy, in the adjuvant or neoadjuvant setting.\n* \u226519 years of age\n* Able to provide verbal consent\n\nExclusion Criteria:\n\n\u2022 Contraindication to central line placement.",
    "sex": "FEMALE",
    "minimumAge": "19 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}